India's COVID-19 Vaccine Development, Manufacturing and Digital Response
India mounted a large-scale vaccine development, manufacturing and digital deployment response to the COVID-19 pandemic. The nationwide vaccination programme began on 16 January 2021 using Covaxin and Covishield, both manufactured domestically. Covaxin was India's first fully indigenous COVID-19 vaccine, developed through a public-private partnership between the Indian Council of Medical Research, its National Institute of Virology in Pune and Bharat Biotech. Covishield was based on Oxford University–AstraZeneca vaccine technology and was manufactured at enormous scale in India by the Serum Institute of India. The campaign was supported by CoWIN, India's population-scale digital vaccination infrastructure for registration, appointments, dose records and digitally verifiable certificates. Together, indigenous vaccine research, pharmaceutical manufacturing capacity and digital public infrastructure enabled India to administer more than two billion COVID-19 vaccine doses while also supplying Indian-made vaccines internationally.
Published by Whitepill on
People involved
Timeline
1 March 2020
ICMR-NIV isolates SARS-CoV-2
Scientists at ICMR's National Institute of Virology in Pune successfully isolated SARS-CoV-2 strains from Indian patients, creating an important foundation for indigenous vaccine research and development.
1 April 2020
ICMR and Bharat Biotech begin indigenous vaccine collaboration
ICMR and Bharat Biotech began collaborating to develop an indigenous COVID-19 vaccine using a SARS-CoV-2 strain isolated at the National Institute of Virology in Pune.
1 May 2020
Virus strain transferred to Bharat Biotech
The SARS-CoV-2 strain isolated by ICMR-NIV was transferred to Bharat Biotech for development of an inactivated whole-virion vaccine that would become BBV152, commercially known as Covaxin.
29 June 2020
Covaxin receives approval for human clinical trials
Bharat Biotech received regulatory approval to begin Phase I and Phase II human clinical trials of Covaxin, moving India's indigenous COVID-19 vaccine candidate into clinical development.
1 July 2020
Covaxin human trials begin
Clinical evaluation of Covaxin began across Indian trial sites to assess the vaccine's safety and immune response.
1 August 2020
Serum Institute begins Indian Covishield trials
ICMR and Serum Institute of India began Phase II and III bridging studies of Covishield in India. Covishield used the Oxford University-AstraZeneca ChAdOx1 vaccine technology, with Serum Institute responsible for Indian trials and large-scale domestic manufacturing.
1 November 2020
Covaxin enters Phase III trials
Bharat Biotech began a large Phase III clinical trial of Covaxin involving approximately 25,800 participants in India, providing large-scale efficacy and safety data for the indigenous vaccine.
3 January 2021
Covaxin and Covishield receive emergency authorization
India's national regulator granted restricted emergency-use authorization to Bharat Biotech's Covaxin and Serum Institute's Covishield, making the two domestically manufactured vaccines the foundation of India's initial COVID-19 vaccination campaign.
16 January 2021
India begins nationwide COVID-19 vaccination
India launched its nationwide COVID-19 vaccination programme using Covaxin and Covishield, initially prioritising healthcare and frontline workers.
16 January 2021
Covaxin enters national deployment
Covaxin's deployment demonstrated India's ability to progress from isolation of the virus strain through vaccine design, preclinical research, clinical trials, manufacturing and national vaccination during a global health emergency.
16 January 2021
CoWIN becomes the digital backbone of India's vaccination programme
Alongside the nationwide vaccination rollout, India deployed CoWIN as the digital infrastructure for managing COVID-19 vaccination. The platform supported beneficiary registration, appointment scheduling, vaccination-session management, dose recording and generation of digitally verifiable vaccination certificates at population scale.
20 January 2021
India begins supplying vaccines abroad
India began supplying domestically manufactured COVID-19 vaccines to other countries through grants and commercial exports under the Vaccine Maitri initiative, leveraging India's position as one of the world's largest vaccine manufacturing centres.
1 March 2021
CoWIN opens self-registration for the public
CoWIN expanded beyond healthcare and frontline workers by enabling eligible members of the public to register and book vaccination appointments online as India progressively widened access to COVID-19 vaccines.
3 March 2021
Covaxin Phase III efficacy results announced
Bharat Biotech announced interim Phase III results showing that Covaxin provided substantial protection against symptomatic COVID-19, adding clinical efficacy evidence to the indigenous vaccine programme.
1 May 2021
Vaccination expands to all adults
India opened COVID-19 vaccination eligibility to everyone aged 18 and above, significantly expanding the scale of the national vaccination programme.
1 May 2021
CoWIN scales for nationwide adult vaccination
As vaccination opened to all adults, CoWIN became the nationwide digital system connecting citizens, vaccination centres and administrators while maintaining dose records across public and private vaccination facilities.
1 June 2021
CoWIN APIs enable third-party integrations
The government made CoWIN APIs available to developers, enabling third-party applications and services to integrate vaccination-centre discovery, availability information and other vaccination-related functionality with the national platform.
3 July 2021
Covaxin final Phase III analysis announced
Bharat Biotech announced the final analysis of its Phase III trial, reporting overall efficacy of approximately 77.8% against symptomatic COVID-19 and strong protection against severe disease.
5 July 2021
India hosts CoWIN Global Conclave
India hosted the CoWIN Global Conclave and offered the technology behind the platform to countries interested in adapting it for their vaccination programmes, positioning CoWIN as an example of Indian digital public infrastructure built for population-scale deployment.
21 October 2021
India administers one billion COVID-19 vaccine doses
India crossed one billion administered COVID-19 vaccine doses, demonstrating the scale at which domestically manufactured vaccines and India's vaccination infrastructure had been deployed.
21 October 2021
CoWIN records vaccination campaign at billion-dose scale
As India crossed one billion administered doses, CoWIN provided nationwide digital infrastructure for recording vaccinations, managing beneficiary records and issuing digitally verifiable certificates.
3 November 2021
WHO grants Emergency Use Listing to Covaxin
The World Health Organization granted an Emergency Use Listing to Bharat Biotech's Covaxin after reviewing its quality, safety and efficacy data, providing international regulatory recognition for India's indigenous COVID-19 vaccine.
3 November 2021
WHO reports 78% efficacy for Covaxin
WHO reported that Covaxin demonstrated approximately 78% efficacy against COVID-19 of any severity 14 or more days after the second dose and noted its suitability for low- and middle-income countries because of relatively straightforward storage requirements.
14 December 2021
Indian vaccine manufacturing reaches massive scale
Serum Institute reported Covishield manufacturing capacity of approximately 250–275 million doses per month, while Bharat Biotech reported Covaxin capacity of approximately 50–60 million doses per month.
3 January 2022
Vaccination expands to adolescents
India expanded its COVID-19 vaccination programme to the 15–18 age group, with Covaxin used for vaccination of eligible adolescents.
17 July 2022
India crosses two billion vaccine doses
India's COVID-19 vaccination programme crossed two billion administered doses, marking one of the largest vaccination efforts undertaken anywhere in the world.
17 July 2022
CoWIN supports vaccination campaign beyond two billion doses
CoWIN served as the digital backbone for India's vaccination campaign as cumulative administered doses crossed two billion, maintaining population-scale vaccination records and digital certification.